Literature DB >> 2117687

Medulloblastoma--prognostic factors and outcome of treatment: review of the Mayo Clinic experience.

G R Garton1, P J Schomberg, B W Scheithauer, E G Shaw, D M Ilstrup, C R Blackwell, E R Laws, J D Earle.   

Abstract

From March 1965 through December 1984, 58 patients (35 male and 23 female patients; median age, 17 years) with posterior fossa (PF) medulloblastoma underwent surgical treatment and postoperative radiation therapy at our institution. Radiation fields were the craniospinal axis in 39 patients, PF plus spinal axis in 12, PF in 6, and whole brain in 1. Median radiation doses were 43 Gy (22 to 60 Gy) to the PF and 34 Gy (6.2 to 50 Gy) to the spinal axis. Overall 5- and 10-year survivals were 50% and 33%, respectively; 5- and 10-year relapse-free survivals were 46% and 32%. Treatment failed in 34 patients (59%): in 18 who had irradiation to the craniospinal axis (13 had received 50 Gy or less to the PF) and in 16 who had a radiation field of less than the craniospinal axis. A statistically significant (P less than 0.05) improvement in 10-year survival was associated with the following prognostic variables: PF dose of 50 Gy or more, whole-brain irradiation, and spinal axis irradiation. In comparison with subtotal resection, total resection was correlated with better 10-year relapse-free survival but not overall survival. All five patients with initial treatment failure only in the spine had received a radiation dose of 30 Gy or less to the spinal axis. The 2-year survival after relapse was 46% with salvage chemotherapy or irradiation in 23 patients and 0% in the 11 patients who received no further treatment (P less than 0.01).

Entities:  

Mesh:

Year:  1990        PMID: 2117687     DOI: 10.1016/s0025-6196(12)62720-7

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  11 in total

1.  A long surviving case of recurrent medulloblastoma displaying effectiveness of ACNU/vincristine chemotherapy.

Authors:  M Miyagami; K Satoh; T Tsubokawa
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 2.  Recent advances in embryonal tumours of the central nervous system.

Authors:  Chitra Sarkar; Prabal Deb; Mehar Chand Sharma
Journal:  Childs Nerv Syst       Date:  2005-01-29       Impact factor: 1.475

3.  Is medulloblastoma the same tumor in children and adults?

Authors:  M T Giordana; P Cavalla; A Dutto; L Borsotti; A Chiò; D Schiffer
Journal:  J Neurooncol       Date:  1997-11       Impact factor: 4.130

4.  Staging, scoring and grading of medulloblastoma. A postoperative prognosis predicting system based on the cases of a single institute.

Authors:  U Sure; W J Berghorn; H Bertalanffy; T Wakabayashi; J Yoshida; K Sugita; W Seeger
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

5.  Are childhood and adult medulloblastomas different? A comparative study of clinicopathological features, proliferation index and apoptotic index.

Authors:  Chitra Sarkar; Pulakesh Pramanik; Asis Kumar Karak; Partho Mukhopadhyay; Mehar Chand Sharma; Varindera Paul Singh; Veer Singh Mehta
Journal:  J Neurooncol       Date:  2002-08       Impact factor: 4.130

6.  Does diagnostic delay result in decreased survival in paediatric brain tumours?

Authors:  Karel Kukal; Milana Dobrovoljac; Eugen Boltshauser; Roland A Ammann; Michael A Grotzer
Journal:  Eur J Pediatr       Date:  2008-06-07       Impact factor: 3.183

7.  Medulloblastoma in adulthood: prognostic factors influencing survival and recurrence.

Authors:  M P Aragonés; R Magallón; C Piqueras; L Ley; J Vaquero; G Bravo
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

8.  Medulloblastoma: clinicopathologic evaluation of 42 pediatric cases.

Authors:  Yeşim Ertan; Murat Sezak; Bengü Demirağ; Mehmet Kantar; Nazan Cetingül; Tuncer Turhan; Yusuf Erşahin; Saffet Mutluer; Yavuz Anacak; Taner Akalin
Journal:  Childs Nerv Syst       Date:  2009-01-13       Impact factor: 1.475

9.  Treatment of recurrent metastatic medulloblastoma with intensive chemotherapy and allogeneic bone marrow transplantation.

Authors:  J H Lundberg; D E Weissman; P A Beatty; R C Ash
Journal:  J Neurooncol       Date:  1992-06       Impact factor: 4.130

10.  Long-term outcomes and role of chemotherapy in adults with newly diagnosed medulloblastoma.

Authors:  Jason A Call; Mihir Naik; Fausto J Rodriguez; Caterina Giannini; Wenting Wu; Jan C Buckner; Ian F Parney; Nadia N Laack
Journal:  Am J Clin Oncol       Date:  2014-02       Impact factor: 2.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.